HCM HUTCHMED (China) Ltd — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$11.18

Period return

-4.26 (-27.59%)

Volume

33.2K

2026-07-21O $11.34 H $11.34 L $11.16 C $11.18MA5 $11.31MA20 $10.97MA60 $11.64MA120 $13.15

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 03. 11.LowBUY4 months ago
B of A Securities: Buy
US analyst rating / recommendation change.
2026. 03. 05.High5 months ago
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2025. 09. 23.MediumSELL10 months ago
Morgan Stanley: Underweight
US analyst rating / recommendation change.
2025. 07. 23.LowBUY12 months ago
B of A Securities: Buy
US analyst rating / recommendation change.
2024. 08. 02.LowHOLD2 years ago
Goldman Sachs: Neutral
US analyst rating / recommendation change.
2024. 06. 30.Medium2 years ago
2025년 2분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2023. 11. 24.MediumBUY3 years ago
Deutsche Bank: Buy
US analyst rating / recommendation change.
2023. 11. 11.LowHOLD3 years ago
Goldman Sachs: Neutral
US analyst rating / recommendation change.
2023. 09. 05.LowBUY3 years ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.
2023. 07. 24.LowBUY3 years ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $22.84 · 15 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 03. 05.	After market close (AMC)	—	—	—	—	—	Scheduled
FY2025 Q2	2024. 06. 30.	Time TBD	—	$0.03	—	—	$305.68M	Reported
FY2024 Q2	2023. 06. 30.	Time TBD	—	$0.19	—	—	$532.87M	Reported
FY2023 Q2	2022. 06. 30.	Time TBD	—	$-0.19	—	—	$202.05M	Reported

HUTCHMED (China) Ltd

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 03. 11.	B of A Securities	—	Maintain	Buy → Buy	—	B of A Securities: Buy
2025. 09. 23.	Morgan Stanley	—	Downgrade	Equal-Weight → Underweight	—	Morgan Stanley: Equal-Weight → Underweight
2025. 07. 23.	B of A Securities	—	Maintain	Buy → Buy	—	B of A Securities: Buy
2024. 08. 02.	Goldman Sachs	—	Maintain	Neutral → Neutral	—	Goldman Sachs: Neutral
2023. 11. 24.	Deutsche Bank	—	Upgrade	Hold → Buy	—	Deutsche Bank: Hold → Buy
2023. 11. 11.	Goldman Sachs	—	Maintain	Neutral → Neutral	—	Goldman Sachs: Neutral